Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Does nebivolol have renoprotective action in patients with chronic kidney disease conditions? An integrative review

Full text
Show less -
Encinas, Jessica Freitas Araujo [1] ; Peiro, Carlos Henrique Foncesca [1] ; Perez, Matheus Moreira [1] ; Raimundo, Joyce Regina Santos [1] ; de Gois, Katharyna Cardoso [1] ; Peres, Marina Cristina [1] ; Draghi, Patricia Ferrante [1] ; Arcia, Catherine Giovanna Costas [1] ; Simoes, Diogo Pimenta [1, 2] ; Murad, Neif [3] ; Alves, Beatriz da Costa Aguiar [1] ; Fonseca, Fernando Luiz Affonso [1, 4] ; da Veiga, Glaucia Luciano [1]
Total Authors: 13
[1] Ctr Univ Saude ABC FMABC, Lab Anal Clin, Santo Andre, SP - Brazil
[2] Univ Municipal Sao Caetano Do Sul USCS, Sao Caetano do Sul - Brazil
[3] Ctr Univ Saude ABC FMABC, Setor Cardiol, Santo Andre, SP - Brazil
[4] Univ Fed Sao Paulo, Dept Ciencias Farmaceut, Campus Diadema, Diadema - Brazil
Total Affiliations: 4
Document type: Review article
Source: European Journal of Pharmacology; v. 905, AUG 15 2021.
Web of Science Citations: 0

Systemic arterial hypertension (SAH) is a chronic disease of multifactorial origin and one of the main risk factors for major adverse cardiovascular events (MACE), which are the leading causes of morbidity and mortality worldwide. The pharmacological treatment of SAH involves five main classes of drugs, and Nebivolol (NEB) is one of those drugs, belonging to the class of third generation 131-adrenoceptors selective blockers. NEB is composed of a racemic mixture of two enantiomers: d-nebivolol, which exerts antagonist effects on 131-adrenoceptors, and l-nebivolol, a vascular 133 receptor agonist. There are several studies that report different actions of NEB, not only for the treatment of SAH, but also as an antioxidant agent or even as a protector of renal damage. The aim of this systematic review was to investigate the available evidence regarding the effects of NEB on kidney diseases, evaluating its possible renoprotective action. (AU)

FAPESP's process: 18/24808-0 - Evaluation of biomarkers of renal damage and inflammatory profile in elderly diabetic rats
Grantee:Glaucia Raquel Luciano da Veiga
Support Opportunities: Regular Research Grants